SCHEMBL4457016

SCHEMBL4457016

Cn1cc(C2CN(S)c3ncc(C4CCC(=O)CC4)cc32)cn1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 2/20 0.33
CSF1R P07333 1/20 0.31
HSD11B1 P28845 1/20 0.30
SPR P35270 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466252 0.87 CREBBP (0.39) CREBBPCSF1RSPR
SCHEMBL4466625 0.81 HRH1 (0.32) SPR
SCHEMBL13463082 0.81 CREBBP (0.34) CREBBP
SCHEMBL4468035 0.79 MAPK8 (0.50)
SCHEMBL13463125 0.79 CREBBP (0.33) CREBBP
SCHEMBL4482885 0.78 MAPK8 (0.50)
SCHEMBL4469558 0.76 DRD3 (0.31)
SCHEMBL19868807 0.75 HSD11B1 (0.43) CREBBPHSD11B1SPR
SCHEMBL4454039 0.72 PDGFRB (0.37)
SCHEMBL4462754 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178552-B2 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-05-15 US disclosed
US-20100069354-A1 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069354-A1 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPK13, MAPKAPK5 CREBBP 373/4885CSF1R 3154/4885HSD11B1 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.